Similar effects have been obtained in BC-bearing mice treated with the immune-stimulator recombinant fusion protein B7.2-IgG in combination with SU6668an, an inhibitor of the tyrosine kinase activity of three angiogenic receptors, namely VEGFR2, PDGFR-beta, and FGFR1 [130]. The gene discussed is CD86; the disease is breast cancer.